The impact of EndoPredict ® on decision making with increasing oncological work experience: can overtreatment be avoided?

ConclusionIt seems that inexperienced physicians may profit from the use of EndoPredict® to avoid an overtreatment. In nodal negative patients and patients with a low Ki67 index, undertreatment can be avoided with the use of EndoPredict® (borderline significance). Further prospective studies with larger study cohorts are needed to further validate this tool.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research

Related Links:

Conclusion: This study showed that the 21-gene RS assay was not able to predict the benefit of PMRT for OS in women with T1-2 N1mic ER-positive HER2-negative breast cancer. However, further prospective larger sample-size trials are warranted to determine if a benefit exists. Introduction According to the latest Global Cancer Statistics 2018, breast cancer is still the most frequent cancer and the leading cause of cancer death among females worldwide (1). It is estimated that there will be about 2.1 million newly diagnosed female breast cancer cases and 627,000 cancer death in 2018 (1). The use of screening tests for ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: The texture analysis for breast DCE-MRI proposed in this study demonstrated potential utility in HER2 2+ status discrimination. Background Human epidermal growth factor receptor 2 (HER2) is an orphan tyrosine kinase receptor. It is reported that HER2 is overexpressed in 15–20% of breast cancers. Overexpression of HER2 in breast cancer correlates with shortened disease-free survival. Compared with HER2-negative patients, patients with HER2-positive breast cancers have a poor prognosis, a high probability of lymph node metastasis and a high risk of recurrence (1–3). However, previous studies h...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
HER-2 (also known as HER-2/neu) is a member of the epidermal growth factor (EGF) receptor family. The amplification of oncogene HER-2 is presented in 20 to 30% of breast cancers and results in an increase of the protein expression. HER-2 over expression has also been shown to correlate with poor prognosis. It is associated with poorly differentiated high grade tumors with lymph node involvement, greater risk of recurrence and relative resistance to some types of chemotherapy. The receptor is however a target for treatment with anti HER-2 antibody trastuzumab (Herceptin). Immunohistochemistry analysis for HER 2 scoring is s...
Source: Bangladesh Medical Research Council Bulletin - Category: International Medicine & Public Health Source Type: research
ConclusionsIn early-stage TNBC, nodal involvement, TILs, and receipt of adjuvant chemotherapy were independently associated with IDFS and OS. In systemically untreated TNBC, TILs remained prognostic and the risk of recurrence or death was substantial, even for T1N0 disease.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusion: Adendom met its primary objective, with 35% of intermediate clinico-pathological risk pts getting significant therapeutic changes upon the receipt of an EPclin gene expression profile. 43% of these "intermediate risk" pts planned for CT avoided it. 12% of the changes were discrepant with the test's results and occurred after discussion with the patient.Citation Format: Kaul R, Risinger AL, Mooberry SL. Eribulin impairs TGF-β type I receptor localization and signaling in BT-549 cells [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: MS, a novel metastasis biomarker reflecting interaction between streaming and metastasizing tumor cells and microenvironment, provides prognostic information complementary to classical clinicopathologic features and RS in HR+/HER2- ESBC. Further evaluation is warranted in order to identify patients at highest risk of recurrence within 5 years most likely to benefit from adjuvant chemotherapy or novel therapies. (Supported by BCRF and NCI CA21115, CA180794, CA23318, CA66636, CA180820).Citation Format: Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton D, D'Alfon...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: General Session Abstracts Source Type: research
CONCLUSIONS: . HSP90AA1 and AB1 genes exhibit low expression in breast cancers highly sensitive to chemotherapy and may indicate the patients with higher probability of pathological complete response. The ratio of HSP90AA1 to proliferation-related markers (CDK1 or MKI67) may be even better predictor of pCR chance, with higher expression of proliferation genes and lower stress response in patients sensitive to chemotherapy. PMID: 28051275 [PubMed - as supplied by publisher]
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
Purpose The aim of this study was to evaluate contemporary rates of local recurrence (LR) and regional recurrence (RR) in young patients with breast cancer in relation to tumor biology as expressed by biomarker subtypes. Patients and Methods Women
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Epidemiology, Surgery, Radiation, Chemotherapy, Combined Modality, Hormonal Therapy, Translational Oncology, Risk factors, Radiation Oncology, Surgical Oncology Breast Cancer Source Type: research
Conclusions: In this low-powered analysis, TIL did not provide significant prognostic information for HER2-positive breast cancer patients treated in the CherLOB study. However, a non-significant trend suggests a positive correlation between increased levels of It-TIL and better EFS. The evaluation of immune gene expression signatures and their correlation with survival is ongoing, results will be available for the meeting.Citation Format: Dieci MV, Bisagni G, Cagossi K, Generali DG, Sarti S, Piacentini F, Conte P, Guarneri V. Survival analysis of the prospective randomized Cher-Lob study: Correlation with tumor infiltrati...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
CONCLUSION: Low mammographic BD, low BMI and early clinical stage were associated with improved pCR rate and lower pathological stage after neoadjuvant chemotherapy. BD had more pronounced association with response to chemotherapy after adjustment with BMI. PMID: 26071795 [PubMed - as supplied by publisher]
Source: Breast - Category: Cancer & Oncology Authors: Tags: Breast Source Type: research
More News: Borderline Tumor | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Germany Health | HER2 | Hormones | OBGYN | Study | Women